Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Celiac disease and liver involvement]

Thierry Thevenot1, Philippe Mathurin, Vincent Di Martino

  • 1Service d'Hépato-Gastroentérologie, Centre Hospitalier de Cambrai. bibliotheque@ch-cambrai.fr

Gastroenterologie Clinique Et Biologique
|February 21, 2003
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

The lancet. Gastroenterology & hepatology·2026
Same author

Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort.

JHEP reports : innovation in hepatology·2026
Same author

Alcohol induces sorafenib resistance in hepatocellular carcinoma: A translational study.

Journal of molecular medicine (Berlin, Germany)·2026
Same author

Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.

European journal of gastroenterology & hepatology·2025
Same author

Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial.

Journal of hepatology·2025